NCT05163496View on ClinicalTrials.gov

Frontline Clinician Psilocybin Study

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

December 30, 2023

Study Completion Date

June 30, 2024

Conditions
Burnout, CaregiverBurnout, ProfessionalCOVID-19DepressionPost Traumatic Stress DisorderMoral Injury
Interventions
DRUG

Psilocybin (Usona Institute)

PAP + psilocybin 25 mg

DRUG

Active placebo

PAP + niacin 250mg

Trial Locations (1)

98195

University of Washington, Seattle

All Listed Sponsors
lead

University of Washington

OTHER